Abstract
Quantitative clinical monitoring of musculoskeletal conditions and inflammatory joint diseases is challenging. Traditional measures to assess rheumatoid arthritis (RA), such as joint assessment, laboratory, imaging, and patient self-report measures, have limitations and provide only a reflection of the underlying inflammatory process. A gold standard to define disease activity in RA does not exist and various indices of disease activity must be used. Standard quantitative monitoring with a treatment goal has been shown to be beneficial to patient outcomes in randomized clinical trials. Quantitative monitoring has also contributed to improved long-term outcomes for RA in clinical care. Challenges of the measures need to be recognized and hurdles identified that prevent quantitative monitoring in every-day clinical care concerning disease activity and beyond. These aspects are discussed in this article.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
